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SUMMARY
Protein aggregates are a common feature of neurodegenerative syndromes. Specific protein
fragments were found previously to be aggregated in disorders including Alzheimer’s disease,
amyotrophic lateral sclerosis, and Parkinson’s disease. Here we show that the natural C-terminal
fragments of Tau, TDP43, and α-synuclein are short-lived substrates of the Arg/N-end rule
pathway, a processive proteolytic system that targets proteins bearing “destabilizing” N-terminal
residues. Furthermore, a natural TDP43 fragment is shown to be metabolically stabilized in
Ate1−/− fibroblasts that lack the arginylation branch of the Arg/N-end rule pathway, leading to
accumulation and aggregation of this fragment. We also found that a fraction of Aβ42, the
Alzheimer’s-associated fragment of APP, is N-terminally arginylated in the brains of 5xFAD mice
and is degraded by the Arg/N-end rule pathway. The discovery that neurodegeneration-associated
natural fragments of TDP43, Tau, α-synuclein, and APP can be selectively destroyed by the Arg/
N-end rule pathway suggests that this pathway counteracts neurodegeneration.
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INTRODUCTION
A common feature of neurodegenerative diseases is the accumulation of intracellular or
extracellular neuronal protein aggregates. The sizes of aggregates vary from molecular-scale
protein oligomers to cytologically conspicuous inclusion bodies. The protein composition of
aggregates tends to be characteristic of specific disorders, and comprises intact proteins,
their protease-generated fragments, and their posttranslationally modified (e.g.,
polyubiquitylated) counterparts. While some aggregates can be cytoprotective, other types
of aggregates, particularly soluble oligomeric species, are often toxic in that they increase
the probability of cell dysfunction and death (Balch et al., 2008; Chen et al., 2011; Eisenberg
and Jucker, 2012; Green, 2011; Kopito, 2000; Lindquist and Kelly, 2011; Prusiner, 2012;
Vabulas et al., 2010; Vendruscolo et al., 2011).
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Aβ is an Alzheimer’s disease (AD)-associated polypeptide of 36 to 43 residues derived from
secretase-mediated cleavages of the amyloid precursor protein (APP). Another AD-
associated protein is Tau, a microtubule-binding protein. Both Aβ and Tau can form
aggregates, largely extracellular in the case of Aβ (Selkoe, 2011; Serrano-Pozo et al., 2011).
TDP43 is an RNA/DNA-binding protein whose intracellular aggregates are associated with
amyotrophic lateral sclerosis (ALS), frontotemporal lobal degeneration (FTLD-TDP), and a
spectrum of related disorders called TDP43 proteinopathies (Lagier-Tourenne et al., 2010;
Lee et al., 2012). Aggregates containing TDP43 or its fragments are often also present in the
brains of patients with Alzheimer’s, Parkinson’s, Pick’s, and other neurodegenerative
syndromes. α-Synuclein is a protein whose aggregates range from oligomers to
cytologically conspicuous Lewy bodies. These aggregates are associated with disorders that
include Parkinson’s disease (PD) and are referred to as synucleinopathies (Dawson et al.,
2010; Rochet et al., 2012).
We describe here the discovery of a mechanistically explicit connection between specific
neurodegeneration-associated proteins and the N-end rule pathway. This pathway targets
proteins containing N-terminal degradation signals called N-degrons, polyubiquitylates these
proteins and thereby causes their processive degradation by the proteasome (Figure S1A, B).
The main determinant of an N-degron is a destabilizing N-terminal residue of a protein.
Recognition components of the N-end rule pathway are called N-recognins. In eukaryotes,
N-recognins are E3 ubiquitin (Ub) ligases that can target N-degrons. Regulated degradation
of proteins by the N-end rule pathway mediates a strikingly broad range of biological
functions, cited in the legend to Figure S1 (reviewed in Dougan and Truscott, 2011; Graciet
and Wellmer, 2010; Mogk et al., 2007; Tasaki et al., 2012; Varshavsky, 2008, 2011).
In eukaryotes, the N-end rule pathway comprises two branches, the Ac/N-end rule pathway
and the Arg/N-end rule pathway. The Ac/N-end rule pathway targets proteins through their
Nα-terminally acetylated (Nt-acetylated) residues, largely Nt-acetylated Met, Ala, Val, Ser,
Thr, or Cys (Hwang et al., 2010). These degradation signals are called Ac/N-degrons, to
distinguish them from other N-degrons (Figure S1B). Implemented by the Ac/N-end rule
pathway, Ac/N-degrons are the largest class of degradation signals in the proteome, as
nearly 90% of human proteins are cotranslationally Nt-acetylated (Hwang et al., 2010;
Varshavsky, 2011).
The Arg/N-end rule pathway recognizes specific unacetylated N-terminal residues (Figure
S1A). N-terminal Arg, Lys, His, Leu, Phe, Tyr, Trp, and Ile are directly recognized by E3
N-recognins. In contrast, N-terminal Asn, Gln, Asp, Glu, and Cys are destabilizing owing to
their preliminary enzymatic modifications, including Nt-deamidation and Nt-arginylation
(Figure S1A) (Brower and Varshavsky, 2009; Tasaki et al., 2012; Varshavsky, 2011).
Previous studies (cited in Results) have identified specific protease-generated fragments of
APP and Tau in aggregates of AD, specific fragments of TDP43 in aggregates of ALS and
FTLD-TDP, and specific fragments of α-synuclein in aggregates of synucleinopathies,
including PD. Here we show that these natural fragments of Tau, TDP43 and α-synuclein
are short-lived substrates of the Arg/N-end rule pathway. We also show that Aβ42, the AD-
associated fragment of APP, can be Nt-arginylated both in vitro and in the brain. Aβ42
tagged with a C-terminal epitope is a short-lived Arg/N-end substrate, and a fraction of
untagged human Aβ42 in mouse brains is degraded by the Arg/N-end rule pathway. The
realization that the aggregation-prone, neurodegeneration-associated fragments of TDP43,
Tau, α-synuclein, and apparently intracellular Aβ42 as well can be processively destroyed
by the Arg/N-end rule pathway suggests that this proteolytic system counteracts
neurodegeneration.
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RESULTS
Natural Fragments of TDP43 As Substrates of the Arg/N-End Rule Pathway
TDP43 is an RNA/DNA-binding protein and component of intracellular aggregates
associated with TDP43 proteinopathies, including ALS (Lee et al., 2012). Specific C-
terminal TDP43 fragments were identified as the predominant components of aggregates
isolated from FTLD-TDP human brains. These fragments were more aggregation-prone than
full-length TDP43 (Igaz et al., 2009; Nonaka et al., 2009; Pesiridis et al., 2011). The N-
terminal residues of these C-terminal TDP43 fragments were Arg208, Asp219, and Asp247
(Figure 1) (Igaz et al., 2009; Nonaka et al., 2009). N-terminal Arg and Asp are destabilizing
in that they can be recognized by the Arg/N-end rule pathway (Figures S1A and S2A).
Our degradation assays employed the Ub reference technique (URT) (Figure S1C), derived
from the Ub fusion technique (Varshavsky, 2005). Cotranslational cleavage of a URT-based
fusion by deubiquitylases produces, at the initially equimolar ratio, a test protein with a
desired N-terminal residue and a “reference” protein such as fDHFR-UbR48, a flag-tagged
derivative of the mouse dihydrofolate reductase (Figure S1C). In URT-based pulse-chase
assays, the labeled test protein is quantified by measuring its level relative to the level of a
stable reference at the same time point. URT-based 35S-pulse-chases were performed in a
transcription-enabled rabbit reticulocyte extract, which has been extensively used to analyze
the Arg/N-end rule pathway (Varshavsky, 2011). The fDHFR-UbR48-X208-TDP43f fusions
(X=Arg, Gln, Glu, Met) tagged with the flag epitope (Figure S1C) were labeled with 35S-
Met/Cys for 10 min at 30°C, followed by a chase, immunoprecipitation with anti-flag
antibody, SDS-PAGE, autoradiography and quantification (Figure 1). The logic of these
assays (Piatkov et al., 2012) involves a comparison between the degradation rates of a
protein bearing a destabilizing N-terminal residue and an otherwise identical protein with an
N-terminal residue such as Val or Met, which are not recognized by the Arg/N-end rule
pathway (Figure S1A). In addition to being more accurate than pulse-chases without a stable
reference, URT assays make it possible to detect and measure the degradation of a test
protein during the pulse (before the chase) (Piatkov et al., 2012).
The natural Arg208-TDP43f fragment was short-lived in reticulocyte extract (initial
posttranslational t1/2 of ~7 min), in comparison to the otherwise identical Met208-TDP43f
(Figure 1B, C). Moreover, ~72% of the 35S-labeled Arg208-TDP43f was degraded during the
10-min pulse (before the chase), in contrast to Met208-TDP43f (Figure 1C). We also
constructed Glu208-TDP43f and Gln208-TDP43f, which contained a secondary and a tertiary
destabilizing N-terminal residue, respectively, instead of the wild-type (wt) N-terminal Arg,
a primary destabilizing residue (Figures 1B, C and S1A). The degradation of Glu208-TDP43f
and Gln208-TDP43f was similar to that of Arg208-TDP43f during the chase (Figure 1B, C).
However, there was little degradation of Glu208-TDP43f and Gln208-TDP43f during the
pulse, in contrast to Arg208-TDP43f (Figure 1C) and in agreement with an expected delay in
the degradation of Glu208-TDP43f and Gln208-TDP43f (compared to Arg208-TDP43f), since
their targeting involves Nt-deamidation and/or Nt-arginylation (Figure S1A).
Pulse-chases of the other two natural TDP43 fragments, Asp219-TDP43f and Asp247-
TDP43f, employed fDHFR-UbR48-X-TDP43f (X=Asp, Met, Val, Arg-Asp) (Figure 1D–G).
The magnitudes of the initial (pre-chase) degradation of these fragments were similar to that
of Arg208-TDP43f. Specifically, ~77% of Asp219-TDP43f and ~67% of Asp247-TDP43f
were destroyed during the 10-min pulse, in comparison to the largely stable Met219-TDP43f
and Val219-TDP43f and the virtually completely stable Met247-TDP43f and Val247-TDP43f
(Figure 1D–G).
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We also constructed Arg-Asp219-TDP43f and Arg-Asp247-TDP43f. These proteins were
DNA-encoded equivalents of the posttranslationally Nt-arginylated Asp219-TDP43f and
Asp247-TDP43f, respectively. Given the immediate (cotranslational) availability of N-
terminal Arg in the DNA-encoded Arg-Asp219-TDP43f and Arg-Asp247-TDP43f, these
proteins were degraded even faster than Asp219-TDP43f and Asp247-TDP43f. Strikingly,
~90% of Arg-Asp219-TDP43f and ~95% of Arg-Asp247-TDP43f, respectively, were
destroyed during the 10-min pulse (before the chase), in comparison to either Met219- and
Val219-TDP43f or to Met247- and Val247-TDP43f, respectively (Figure 1D–G).
In Vivo Degradation of Asp247-TDP43 by the Arg/N-End Rule Pathway
URT (Figure S1C) was also used to examine the degradation of the natural Asp247-TDP43f
fragment and its mutants in human 293T cells. Asp247-TDP43f was highly unstable in 293T
cells, with t1/2 of ~5 min (Figure 2B). Moreover, similarly to the results with reticulocyte
extract (Figure 1F), ~76% of Asp247-TDP43f was degraded in 293T cells during the 15-
min 35S-pulse, compared to the otherwise identical Val247-TDP43f (Figure 2A, B). We also
examined Arg-Asp247-TDP43f, a DNA-encoded equivalent of the posttranslationally Nt-
arginylated Asp247-TDP43f. Similarly to the results with reticulocyte extract (Figure 1F) and
for the same reasons (described above), Arg-Asp247-TDP43f was degraded even faster than
Asp247-TDP43f, with ~90% of Arg-Asp247-TDP43f destroyed during the pulse, in
comparison to Val247-TDP43f (Figure 2A, B).
In Vivo Aggregation of Asp247-TDP43
Immunofluorescence microscopy indicated an increased in vivo aggregation propensity of
TDP43 fragments compared with full-length TDP43 (Furukawa et al., 2011), in agreement
with biochemical evidence (Igaz et al., 2009; Pesiridis et al., 2011). However, in addition to
the use of the strong PCMV promoter, the TDP43 fragments examined byFurukawa et al.
(2011) were not their natural versions, as they contained N-terminal Met, which is not
recognized by the Arg/N-end rule pathway. By contrast, the aggregation-prone TDP43
fragments Asp208-TDP43, Asp219-TDP43 and Asp247-TDP43, which were predominant
components of aggregates in FTLD-TDP human brains, have been shown here to be short-
lived substrates of the Arg/N-end rule pathway (Figures 1 and 2A, B).
To address the metabolic stability of a TDP43 fragment as an aspect of its in vivo
aggregation propensity, we expressed the mCherry-UbR48-Asp247-TDP43f fusion from the
relatively weak PSV40 promoter in mouse embryonic fibroblasts (EFs) or in Ate1−/− EFs that
lacked Nt-arginylation (Figures 2C–E and S1A). The cotranslational in vivo cleavage of a
URT-type fusion such as mCherry-UbR48-Asp247-TDP43f by deubiquitylases yielded the
stable red-fluorescent mCherry-UbR48 and the natural Asp247-TDP43f fragment whose C-
terminal flag tag was detected using a fluorescein-conjugated secondary antibody (Figure
2C–E).
The use of URT made it possible to unambiguously identify transfected EF cells through
their red fluorescence, irrespective of whether or not these cells were capable of Nt-
arginylation, i.e., irrespective of the steady-state levels of the natural Asp247-TDP43f
fragment, whose degradation required Nt-arginylation (Figures 1F, 2C–E and S1A).
Remarkably, whereas ~90% of transfected wt EF cells (identifiable through their red
fluorescence) did not contain detectable levels of the rapidly degraded Asp247-TDP43f
fragment, ~57% of transfected Ate1−/− EFs (in which Asp247-TDP43f was long-lived, owing
to the absence of Nt-arginylation), contained high levels of Asp247-TDP43f, present largely
in cytosolic aggregates (Figure 2C–E). Thus, the rate of degradation of a cleavage-
generated, aggregation-prone protein fragment by the Arg/N-end rule pathway can have a
major influence on the extent of this fragment’s aggregation in living cells.
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Natural Fragment of α-Synuclein As a Substrate of the Arg/N-End Rule Pathway
α-Synuclein is a membrane-associated neuronal protein that functions in vesicular
trafficking (Rochet et al., 2012). In vivo aggregation of α-synuclein can result in toxic
oligomers and the eventual formation of larger aggregates called Lewy bodies (Cremades et
al., 2012). Proteases such as calpains and metalloproteinase-3 (MMP3) (the latter is usually
extracellular but can occur in the cytosol as well) can cleave α-synuclein and contribute to
the formation of Lewy bodies, which contain both full-length α-synuclein and its fragments
(Choi et al., 2011; Levin et al., 2009). In particular, the cleavage of human α-synuclein by
MMP3 between Ala78 and Gln79 yielded the N-terminal and C-terminal fragments that were
more aggregation-prone than full-length α-synuclein (Choi et al., 2011).
The Gln79-synuclein fragment of the 140-residue human α-synuclein is a predicted substrate
of the Arg/N-end rule pathway (Figures 3A, B and S1A). Using URT-based pulse-chases,
we found that the Gln79-synuclein fragment was indeed short-lived, and was targeted
exclusively by the Arg/N-end rule pathway in reticulocyte extract, as the otherwise identical
Val79-synuclein was completely stable under the same conditions (Figure 3A–C).
Epitope-Tagged Aβ As a Substrate of the Arg/N-End Rule Pathway
Aβ is an amyloidogenic polypeptide of 36 to 43 residues, produced through cleavages of
APP by secretases. The 42-residue Aβ, termed Asp-Aβ42 (it bears N-terminal Asp), is a
particularly amyloidogenic species (Figure 4A) (Huang and Mucke, 2012). Aβ-based
aggregates include the extracellular senile plaques as well as soluble Aβ oligomers (either
extracellular or intracellular), which are particularly toxic (Selkoe, 2011).
The N-terminal Asp of Aβ42 is a secondary destabilizing residue in the Arg/N-end rule
pathway (Figures 4A and S1A). To determine whether Asp-Aβ42 could be Nt-arginylated in
vitro, chemically synthesized Asp-Aβ42 was incubated with purified mouse Ate1 R-
transferase (Figure S1A), in a reaction mixture containing 14C-arginine and other
components of the Nt-arginylation assay. Asp-Aβ42 was efficaciously Nt-arginylated by all
examined isoforms of R-transferase, yielding Arg-Asp-Aβ42 (Figure 4D).
We used the URT assay (Figure S1C) to determine whether Asp-Aβ4213myc, bearing a C-
terminal 13-myc epitope (to increase solubility of Asp-Aβ42), would be an efficacious Arg/
N-end rule substrate. Asp-Aβ4213myc was rapidly degraded (Figure 4B, lanes 1–3). The
degradation of type-1 Arg/N-end rule substrates (Figure S1A) can be selectively inhibited in
reticulocyte extract by a dipeptide such as Arg-Ala, which bears a type-1 (basic)
destabilizing N-terminal residue and binds to type-1 substrate-binding sites of N-recognins
(Piatkov et al., 2012; Varshavsky, 2011). Indeed, the addition of Arg-Ala abolished the
degradation of Asp-Aβ4213myc, in contrast to the addition of Ala-Arg (N-terminal Ala is not
recognized by the Arg/N-end rule pathway) (Figure 4B, lanes 4–6 vs. lanes 7–9, Figure 4C,
and Figure S1A).
Asp-Aβ4213myc was also examined in the yeast Saccharomyces cerevisiae, using the URT
assay and fDHFR-UbR48-X-Aβ4213myc fusions that yielded X-Aβ42myc13 (X=Asp, Val,
Met, Arg-Asp) upon their cotranslational cleavage by deubiquitylases. Whereas little or no
Asp-Aβ4213myc was detected at steady-state in wt S. cerevisiae, high levels of Asp-
Aβ4213myc were present in mutants such as ate1Δ (lacking R-transferase and therefore
unable to Nt-arginylate Asp-Aβ4213myc) and ubr1Δ (lacking the N-recognin of the Arg/N-
end rule pathway) (Figure S1A). In contrast, the otherwise identical Val-Aβ4213myc and
Met-Aβ4213myc, whose N-terminal residues are not recognized by the Arg/N-end pathway
(Figure S1A), were present at high levels in all genetic backgrounds (Figure 4E).
Furthermore, Arg-Asp-Aβ4213myc was absent (short-lived) in ate1Δ cells, because the
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degradation of Arg-Asp-Aβ4213myc does not require Nt-arginylation, in contrast to Asp-
Aβ4213myc. In contrast and consistently, Arg-Asp-Aβ4213myc was present (long-lived) in
ubr1Δ S. cerevisiae(Figure 4E). The same fDHFR-UbR48-X-Aβ4213myc fusions were also
used to perform 35S-pulse-chase assays with X-Aβ4213myc (X=Asp, Met, Arg-Asp),
yielding results in agreement with steady-state assays (Figure S4 vs. Figure 4E).
In analogous assays with mammalian cells, fDHFR-UbR48-X-Aβ4213myc (X=Asp, Met, Arg-
Asp) were expressed in immortalized mouse EF cells. In agreement with S. cerevisiae
results (Figure 4E), Asp-Aβ4213myc was metabolically stabilized and therefore detectable
both in Ate1−/− EFs (lacking R-transferase and Nt-arginylation) and in Ubr1−/− Ubr2−/−
double-mutant EFs, which lacked two of the four mouse N-recognins (Figures S1A and 5C)
(Varshavsky, 2011). In contrast, Asp-Aβ42myc13 was not detected in wt EFs, owing to its
degradation (Figure 5C). Consistently, Arg-Asp-Aβ4213myc (whose degradation did not
require Nt-arginylation (Figure S1A)) was detectable in Ubr1−/− Ubr2−/− EFs but neither in
wt EFs nor in Ate1−/− EFs (Figure 5C). Finally and also consistently, Met-Aβ4213myc was
detectable in all three EF cell lines (Figure 5C).
Together, the evidence with purified R-transferase isoforms, reticulocyte extract, and with
yeast and mammalian cells indicated, first, that the untagged Asp-Aβ42 is an efficacious
substrate for Nt-arginylation, and also that the C-terminally tagged Asp-Aβ4213myc is
rapidly destroyed by the Arg/N-end rule pathway both in vitro and in vivo (Figures 4, 5C,
and S4).
Arginylated Human Arg-Asp-Aβ in 5xFAD Mouse Brains
While the bulk of newly formed Asp-Aβ42 is extracellular, at least some extracellular Asp-
Aβ42 can re-enter cells. A fraction of the newly formed Asp-Aβ42 is also intracellular,
being present in endosomal/lysosomal vesicles, in the cytosol, and in the mitochondrial
matrix (Manczak et al., 2006; Selkoe, 2011). If, similarly to the C-terminally tagged Asp-
Aβ4213myc (Figures 4, 5C and S4), at least some untagged Asp-Aβ42 is accessible to the
cytosolic/nuclear Ate1 R-transferase (Figure S1A), Asp-Aβ42 would be expected to be Nt-
arginylated and destroyed by the Arg/N-end rule pathway.
To determine whether Nt-arginylated Arg-Asp-Aβ42 is produced in the brain, we prepared
an antibody to RDAEFRHDSGY, the Nt-arginylated sequence of Asp-Aβ42 (Figure 5A).
This antibody, termed antiR-Aβ, was affinity-purified both “positively” (against
RDAEFRHDSGY) and “negatively” (against DAEFRHDSGY), resulting in a striking
specificity for RDAEFRHDSGYC (Figure 5A). The specificity of antiR-Aβ was such that
there was no signal even with the highest (1 µg) tested level of the RDVEIQGHTSFC
peptide, derived from Nt-arginylated BRCA1 (Piatkov et al., 2012), whose N-terminal
sequence RDVE differed from RDAE of Arg-Asp-Aβ42 only at position 3 (Figure 5A). We
also found that antiR-Aβ could detect either the posttranslationally formed (Nt-arginylated)
Arg-Asp-Aβ4213myc (in ubr1Δ S. cerevisiae) or the cotranslationally formed Arg-Asp-
Aβ4213myc, through its expression from DNA encoding Arg-Asp-Aβ4213myc (Figure 5B).
Consistently, the same assay with antiR-Aβ indicated the absence of Arg-Asp-Aβ4213myc in
extracts from arginylation-lacking ate1Δ S. cerevisiae that expressed Asp-Aβ4213myc
(Figure 5B).
AntiR-Aβ was used to probe brain extracts from non-transgenic (non-Tg) mice versus
5xFAD mice that expressed human APP and SP1 (a subunit of γ-secretase) transgenes
encoding five mutations found in familial forms of AD. 5xFAD mice accumulate high levels
of Asp-Aβ42 by 2 months of age, and exhibit significant Aβ plaque burden throughout the
brain by 6 months of age (Oakley et al., 2006). Since only a fraction of Asp-Aβ42 was
expected to be intracellular and (in principle) accessible to R-transferase, and since Nt-
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arginylation of Asp-Aβ42 would target it for destruction by the proteasome-dependent Arg/
N-end rule pathway (Figure S1A), it would have been unsurprising if steady-state levels of
Arg-Asp-Aβ42 (the species recognized by antiR-Aβ) would be negligible in the brains of
5xFAD mice in the absence of proteasome inhibition. To increase the likelihood of detecting
Arg-Asp-Aβ42, four ~7 months old 5xFAD mice and four age-matched control (non-Tg)
mice were injected with inhibitors of both the proteasome and neprilysin (the latter a
metalloprotease that can degrade extracellular Asp-Aβ42) 12 hrs prior to the preparation of
brain extracts. Proteins were sequentially extracted from isolated brains with Tris-Buffered
Saline (TBS), TBS plus 1% Triton-X100 (TBS-X), and 70% HCOOH (formic acid (FA)),
fractionated by SDS-PAGE and probed with either antiR-Aβ or 4G8 (antiAβ), which
recognized both unmodified Asp-Aβ42 and its derivatives.
Consistent with specificity of antiAβ for human Asp-Aβ, distinct Aβ species, including an
SDS-resistant Aβ oligomer of ~14 kDa, were detected by this antibody in extracts from
5xFAD brains but not in non-Tg mice (Figure 5D, lanes 2, 4, 6 vs. lanes 1, 3, 5).
Remarkably, immunoblotting with antiR-Aβ antibody identified a distinct endogenous Arg-
Asp-Aβ42 in FA (formic acid) extracts from brains of 5xFAD mice that were treated with
inhibitors that included proteasome inhibitors. In striking contrast, the band of Arg-Asp-
Aβ42 was absent from either untreated 5xFAD mice or from non-Tg mice treated with
protease inhibitors (Figure 5E, lane 2 vs. lanes 1, 5). In other words, detectable steady-state
levels of Arg-Asp-Aβ42 were present exclusively in the brains of 5xFAD mice that had
been treated with inhibitors of two proteases (including the proteasome), i.e., Arg-Asp-Aβ42
was absent from otherwise identical but untreated 5xFAD brains. Given high specificity of
antiR-Aβ antibody for Arg-Asp-Aβ42 (Figure 5A, B), these results (Figure 5E) strongly
suggested that endogenous Arg-Asp-Aβ42 (Nt-arginylated Asp-Aβ42) was formed but
short-lived in 5xFAD brains, and became detectable only when the Arg/N-end rule pathway
was partially inhibited (Figure 5E).
Similarly to the absence of Arg-Asp-Aβ42 from the brains of untreated 5xFAD mice, no
Arg-Asp-Aβ42 was observed in human brains of an AD patient and a non-AD control
(Figure 5E, lanes 3, 4 vs. lanes 1,2, 5), suggesting that the endogenous intracellular Asp-
Aβ42 in human brains is Nt-arginylated and short-lived through the degradation of Arg-
Asp-Aβ42 by the Arg/N-end rule pathway. In contrast to human brains, for which this
interpretation remains a conjecture, it was strongly supported by assays with brains from
5xFAD mice (Figure 5E, lanes 2 vs. lanes 1, 5).
Natural Fragment of Tau As a Substrate of the Arg/N-End Rule Pathway
Tau, a microtubule-associated protein, is a part of intracellular oligomers and larger
aggregates, called neurofibrillary tangles (NFT), that are characteristic of AD, in
conjunction with Asp-Aβ42. Tau and its fragments are associated with neurodegenerative
disorders that are referred to as tauopathies and include AD and many cases of FTLD
(Prusiner, 2012; Selkoe, 2011). Tau can be cleaved by calpains or caspases. The resulting
fragments tend to be more aggregation-prone and toxic than full-length Tau (Spires-Jones et
al., 2011).
One natural fragment of human Tau (isoform 2N) is Glu3-Tau-2N124, which is produced by
calpains through cleavages between Ala2 and Glu3 and between Gln124 and Ala125 (Figure
3D) (Garg et al., 2011). The Glu3-Tau-2N124 fragment bears N-terminal Glu, a destabilizing
residue (Figure S1A). Using URT-based fusions, we found that Glu3-Tau-2N124 was an
Arg/N-end rule substrate in reticulocyte extract, with the posttranslational t1/2 of ~52 min. In
contrast, the posttranslational t1/2 of its Val3-Tau-2N124 counterpart was ~180 min (Figure
3E, F). Moreover, ~50% of the initially 35S-labeled Glu3-Tau-2N124 was degraded during
the 10-min pulse, in contrast to Val-Tau-2N3–124 (Figure 3E, F). Another splicing-derived
Brower et al. Page 7
Mol Cell. Author manuscript; available in PMC 2014 April 25.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Tau isoform, Tau-1N, lacks exon 3 (Figure S3A). Strikingly, ~78% of the initially 35S-
labeled Glu3-Tau-1N95 was degraded during the 10-min pulse, in contrast to Val3-Tau-1N95
(Figure S3C). The slow but detectable degradation of both Val3-Tau-2N124 and Val3-
Tau-1N95 (Figures 3E, F and S3B, C) indicates the presence of a (relatively weak) internal
degron(s) in Glu3-Tau-2N124 and Glu3-Tau-1N95, in addition to their efficacious N-degrons.
DISCUSSION
Here we have shown that specific, naturally occurring and aggregation-prone fragments of
neurodegeneration-associated TDP43, Tau, and α-synuclein are short-lived substrates of the
Arg/N-end rule pathway, a processive proteolytic system that targets proteins with
destabilizing N-terminal residues (Figures 1–3 and S1–S3). By expressing a natural
fragment of TDP43 (that we showed is an Arg/N-end rule substrate) in wt mouse fibroblasts
and in their Ate1−/− counterparts unable to degrade this fragment, we also found that the rate
of destruction of an aggregation-prone fragment by the Arg/N-end rule pathway has a major
influence on protein aggregation in living cells (Figure 2C–E). Through a decrease in the in
vivo levels of an aggregation-prone protein, its selective degradation would slow down the
formation of an aggregation-nucleating protein oligomer, a key intermediate in the growth of
larger aggregates. We also found that Asp-Aβ42, the Alzheimer’s-associated 42-residue
fragment of APP, can be N-terminally arginylated not only in vitro but also in vivo, in the
brain (Figures 4A, D and 5E). Moreover, at least a fraction of Asp-Aβ42 is apparently
degraded by the Arg/N-end rule pathway in the brains of 5xFAD mice that overexpress
human Asp-Aβ42 (Figure 5E).
The discovery that several major natural fragments of neurodegeneration-associated proteins
can be selectively destroyed by the Arg/N-end rule pathway (Figures 1–5 and S1–S4)
suggests that this pathway counteracts neurodegeneration. The anti-neurodegeneration
function of the Arg/N-end rule pathway suggested by these results remains to be explored in
detail through controlled alterations of the activity of this pathway in animal models of
specific neurodegeneration syndromes.
N-terminal Arg208, Asp219, and Asp247 of the natural human TDP43 fragments are P1’
residues in the corresponding cleavage sites of full-length TDP43 (Figures 1 and S2A). (A
P1’ residue becomes N-terminal upon the cleavage (Figure S2).) Except for telling instances
described below, these P1’ residues were found to be conserved at least among vertebrates.
The informative exceptions, vis-à-vis the Arg208 P1’ residue of human TDP43, were the
mouse, rat and chicken TDP43, which contained Gln (Q), instead of Arg (R), at the P1’
position (Figure S2A). Remarkably, however, both N-terminal Gln and Arg are destabilizing
residues recognized by the Arg/N-end rule pathway (Figure S1A).
The natural Gln79-synuclein fragment was also found to be a short-lived Arg/N-end rule
substrate (Figures 3A–C and S1A). Similarly to the TDP43 fragments, the identity of the
Gln79 P1’ residue of α-synuclein in its MMP3 cleavage site is largely but incompletely
conserved among vertebrates. Whereas most vertebrates, including humans, dogs, mice, rats
and horses, contain Gln at the P1’ position of the cleavage site, some mammals (such as
guinea pigs), some frogs (such as Xenopus laevis), and some fishes (such as pikes) contain
His at the P1’ position of their α-synucleins (Figure S2B). Remarkably, both N-terminal Gln
and His are destabilizing residues recognized by the Arg/N-end rule pathway (Figure S1A).
The natural human Glu-Tau-2N3–124 fragment of Tau is also a short-lived Arg/N-end rule
substrate (Figure 3D–F). In yet another example of the “drift-with-constraint” evolutionary
pattern seen above with TDP43 and α-synuclein (Figure S2A, B), the P1’ residue at position
3 of the calpain cleavage site of Tau is Glu in humans, horses, rats, chickens and other
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examined vertebrates, but is Asp in mice (Figure S2C). However, both Glu and Asp are
destabilizing residues (Figure S1A), and therefore the mouse Asp-Tau-2N counterpart of the
human Glu-Tau-2N fragment is also a predicted Arg/N-end rule substrate.
The invariably present evolutionary constraint of this kind, observed with both TDP43, α-
synuclein and Tau fragments (Figure S2), would be expected if a short in vivo half-life of a
C-terminal fragment of a full-length precursor would be a fragment’s adaptive property,
maintained by selection during evolution. Together with our findings about natural
fragments of other proteins (Piatkov et al., 2012; Varshavsky, 2012), these results (Figures
1–3 and S2) further support, through a conceptually independent argument, the function of
the Arg/N-end rule pathway as a repressor of neurodegeneration. They also indicate adaptive
(fitness-increasing) evolutionary origins of the observed destabilizing P1’ residues in the
precursors of the cited TDP43, α-synuclein, and Tau fragments.
Although R-transferase is active throughout the brain (Varshavsky, 2011), the N-termini of
the Asp219-TDP43 and Asp247-TDP43 fragments, which were extracted from aggregates in
FTLD-TDP human brains, bear the unmodified N-terminal Asp (Igaz et al., 2009; Nonaka et
al., 2009). In other words, these N-termini have not been Nt-arginylated in FTLD-TDP
brains, despite being efficacious substrates of R-transferase, as indicated by our results
(Figures 1 and 2). A plausible explanation is that the initial oligomerization of a protease-
generated C-terminal protein fragment (e.g., Asp247-TDP43; Figures 1F, G and 2) may
sterically sequester the N-terminus of a fragment, thereby precluding its Nt-arginylation.
This oligomerization may occur rapidly enough after the protease-mediated cleavage of a
full-length precursor (e.g., full-length TDP43) to shield a significant fraction of a newly
formed C-terminal fragment. The rest of this fragment, i.e., those of its molecules that were
not sequestered rapidly enough, would be Nt-arginylated and degraded by the Arg/N-end
rule pathway. The latter process can account for negligible levels of, e.g., the Arg-Asp247-
TDP43 fragment in aggregates from FTLD-TDP brains. In this interpretation, which is
relevant to all aggregation-prone Arg/N-end rule substrates, the rate of proteolytic targeting,
by the Arg/N-end rule pathway, of a newly formed protein fragment can determine the
extent to which this fragment escapes degradation through its initial oligomerization that
sequesters its N-degron.
An alternative possibility is that the cleavages giving rise to Nt-arginylatable fragments may
take place after the formation of aggregates, i.e., within aggregates, presumably by a co-
aggregated protease. This interpretation is unlikely at least in the case of Asp219-TDP43 and
Asp247-TDP43, because aggregates would be expected, then, to contain N-terminal TDP43
fragments as well. To the contrary, only C-terminal TDP43 fragments were recovered from
aggregates in FTLD-TDP brains (Igaz et al., 2009). Possible fates of N-terminal protein
fragments are considered below.
Our evidence that the neurodegeneration-associated C-terminal fragments of proteins such
as TDP43, Tau, and α-synuclein are short-lived substrates of the Arg/N-end rule pathway is
confined, at present, to soluble fragments (Figures 1–3, S1–S3). However, it is also possible
that the Arg/N-end rule pathway, being a Ub/ATP/proteasome-mediated mechanochemical
proteolytic system, might target and destroy these fragments not only in their soluble states
but also, for example, on the surfaces of fragment-containing protein aggregates. This idea
implies that the Arg/N-end rule pathway may influence equilibria that determine whether a
specific in vivo aggregate grows or disappears, or whether it forms in the first place. If so, it
is possible that the number and initial levels of protease-generated protein fragments in a
cell are significantly larger than is currently observed, i.e., that many C-terminal fragments
have not been detected so far, owing to their low steady-state levels, the result of their
efficacious destruction by the Arg/N-end rule pathway. More generally, our results suggest
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that the in vivo dynamics of aggregation-prone protein fragments, including their ability to
form either cytoprotective or cytotoxic aggregates depends, in particular, on the activity of
the Arg/N-end rule pathway. Its down-regulation during aging (Gabius et al., 1983) may be,
therefore, among the causes of aging-associated neurodegeneration.
The absence of the N-terminal counterparts of C-terminal TDP43 fragments such as Arg208-
TDP43, Asp219-TDP43 and Asp247-TDP43 (Figures 1 and 2) from aggregates in FTLD-
TDP brains (Igaz et al., 2009) implies either a low aggregation propensity of N-terminal
fragments or, mutually nonexclusively, their efficacious degradation. If the latter possibility
proves correct at least for some N-terminal TDP43 fragments that form concurrently with C-
terminal fragments (identified here as short-lived Arg/N-end rule substrates), a verifiable
possibility is that these N-terminal fragments may become short-lived (relative to full-length
precursors) owing to re-activation of their Ac/N-end degrons that were sterically sequestered
in uncleaved proteins. Ac/N-degrons are implemented by the Ac/N-end rule pathway
(Figure S1B). These recently discovered degrons, created by Nt-acetylation (Hwang et al.,
2010), are the largest class of degradation signals in the proteome, as nearly 90% of human
proteins are Nt-acetylated.
Although the Arg/N-end rule and Ac/N-end rule branches of the N-end rule pathway are
multifunctional and mechanistically complex, they comprise but a subset of the even larger
Ub system. Its many functions include protein homeostasis, in conjunction with the N-end
rule pathway. Both our present results and the earlier understanding (Varshavsky, 2011)
indicate that the ability of the N-end rule pathway to destroy proteins by recognizing their
specific N-terminal residues is a unique attribute vis-à-vis the rest of the Ub system. This
exclusive property of both the Arg/N-end rule pathway and the Ac/N-end rule pathway
(Figure S1) is likely to play a major role in down-regulating protease-generated protein
fragments that are formed in the entire gamut of neurodegenerative disorders, including
ALS, FTLD-TDP, PD, and AD. The mechanistically specific connection between the Arg/
N-end rule pathway and neurodegeneration-associated protein fragments that has been
discovered in the present work (Figures 1–5 and S1–S4) can now be explored through
detailed N-end rule studies in the context of animal models of neurodegenerative syndromes.
EXPERIMENTAL PROCEDURES
Plasmids, Miscellaneous Reagents, Animal Care, and Treatments of Mice
Plasmids, constructed by standard methods, are described in Tables S1 and S2. 5xFAD mice
were obtained from Jackson Laboratories. Care and treatments of mice were performed
according to the relevant NIH guidelines, as described in Supplemental Experimental
Procedures.
In Vitro and in Vivo Degradation Assays
The in vitro transcription-translation-degradation assays employed the TNT T7 Coupled
Transcription/Translation System (Promega) (Piatkov et al., 2012). S. cerevisiae strains and
degradation assays used with them have also been described (Hwang et al., 2010). Mouse
NIH-3T3 and human HEK-293T cells were transfected using Lipofectamine-2000
(Invitrogen), followed by either steady-state measurements, 35S-pulse-chases, or
fluorescence microscopy assays, as described in Supplemental Experimental Procedures.
Antibody Specific for Arg-Asp-Aβ and In Vitro Arginylation Assay
Positive/negative affinity purification procedures that were employed to produce antibody
recognizing Nt-arginylated Arg-Asp-Aβ42, as well as in vitro arginylation assays with
synthetic Asp-Aβ42 are described in Supplemental Experimental Procedures.
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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HIGHLIGHTS
• Neurodegeneration-associated fragments bear destabilizing N-terminal residues.
• Destabilizing activity of these N-terminal residues is conserved in evolution.
• Neurodegeneration-associated fragments are Arg/N-end rule substrates.
• The Arg/N-end rule pathway may be a repressor of neurodegeneration.
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Figure 1. C-Terminal TDP43 Fragments From Aggregates in the Brains of Patients with
Frontotemporal Lobal Degeneration (FTLD-TDP) As Short-Lived N-End Rule Substrates
(A) Domain organization of human TDP43. Arrowheads indicate the cleavage sites. RRM1,
RRM2, RNA-binding domains.
(B) The cleavage site 1 is indicated by an arrowhead, with the P1’ residue (Arg) in red.
X208-TDP43f fragments, produced from fDHFR-UbR48-X208-TDP43f (X=Arg, Gln, Glu,
Met), were expressed in reticulocyte extract and labeled with 35S-Met/Cys for 10 min at
30°C, followed by a chase, immunoprecipitation with anti-flag antibody, SDS-PAGE, and
autoradiography. Indicated molecular masses of proteins in this and other panels include
their ~1 kDa flag epitope.
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(C) Quantification of B using the 33 kDa reference protein fDHFR-UbR48.
(D) Same as B but with X219-TDP43f fragments (X=Asp, Arg-Asp, Met, Val).
(E) Quantification of D.
(F) Same as B but with X247-TDP43f fragments (X=Asp, Arg-Asp, Met, Val).
(G) Quantification of F.
See also Figure S1.
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Figure 2. In Vivo Degradation and Aggregation of X247-TDP43f fragments
(A) Pulse-chase assays with X247-TDP43f, produced from fDHFR-UbR48-X247-TDP43f
(X=Asp, Val, Arg-Asp). The fusion proteins were expressed in transiently transfected
human HEK-293T cells, which were labeled with 35S-Met/Cys for 15 min at 37°C, followed
by a chase, preparation of extracts, immunoprecipitation with anti-flag, SDS-PAGE, and
autoradiography. For designations, see the legend to Figure 1B.
(B) Quantification of A.
(C) Diagram of the mCherry-UbR48-Asp247-TDP43f fusion. The arrowhead indicates the site
of cleavage by deubiquitylases (Figure S1C).
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(D) Representative images of either Ate1−/−(upper panels) or wt (lower panels) mouse EF
cells transfected with a plasmid expressing mCherry-UbR48-Asp247-TDP43f. The mCherry
moiety of mCherry-UbR48 was detected by red fluorescence, and the Asp247-TDP43f
fragment was detected by indirect immunofluorescence, using anti-flag antibody and a
fluorescein-conjugated secondary antibody. White bars indicate 10 µm.
(E) Percentage of mCherry-positive cells containing Asp247-TDP43f aggregates, with
surveys of > 1,000 mCherry-positive cells of the wt and Ate1−/− genotypes. The error bars
indicate SEM (standard error of measurement). Statistical analyses employed the unpaired t-
test (p <10−12).
See also Figure S2A.
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Figure 3. Neurodegeneration-Associated C-Terminal Fragments of Human α-Synuclein and Tau
As Short-Lived N-End Rule Substrates
(A) Domain organization of human α-Synuclein. Arrowhead indicates the metalloprotease
cleavage site.
(B) The cleavage site is indicated by an arrowhead, with the P1’ Gln (Q) residue in red. X79-
αSynf, produced from fDHFR-UbR48-X-αSynf (X= Gln, Val) in reticulocyte extract, were
assayed as described in the legend to Figure 1B.
(C) Quantification of B using the reference fDHFR-UbR48.
(D) Domain organization of human Tau-2N. Arrowheads indicate the calpain cleavage sites.
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(E) Same as B but with X3-Tau-2Nf, produced from fDHFR-UbR48-X3-Tau-2Nf (X=Glu,
Val).
(F) Quantification of E.
See also Figure S3.
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Figure 4. N-Terminal Arginylation of Aβ42, and the Degradation of C-terminally Tagged Aβ42
by the Arg/N-End Rule Pathway
(A) Human APP near its transmembrane domain, indicated by yellow rectangle. Arrowheads
indicate the cleavage sites by secretases that yield Aβ42, termed Asp-Aβ42 and indicated by
a red square parenthesis.
(B) C-terminally tagged Asp-Aβ4213myc (produced from fDHFR-UbR48-Asp-Aβ4213myc)
was assayed in reticulocyte extract as described in the legend to Figure 1B, with either no
added dipeptides (lanes 1–3), or 5 mM Arg-Ala (lanes 4–6), or Ala-Arg (lanes 7–9).
(C) Quantification of B.
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(D) Nt-arginylation of Asp-Aβ42 by isoforms of mouse Ate1 R-transferase. 0.1 or 1 µg of
Ate1-1 (lanes 3, 4), Ate1-2 (lanes 5, 6), Ate1-3 (lanes 7, 8), and Ate1-4 (lanes 9, 10) were
incubated for 30 min at 37 °C with 20 µg of chemically synthesized Asp-Aβ42, [14C]-L-
arginine, and other components of the Nt-arginylation assay, followed by SDS/PAGE and
autoradiography. Lane 1, complete reaction (including equal amounts of all four Ate1
isoforms, 1 µg total) but no added Asp-Aβ42. Lane 2, same as lane 3 but without Ate1.
Upper panel: immunoblotting with antibody to mouse Ate1. Middle panel: autoradiography
to detect 14C-labeled Arg-Asp-Aβ42. Lower panel: immunoblotting with anti-4G8 antibody
to detect Asp-Aβ42 or Arg-Asp-Aβ42.
(E) Steady-state levels of X-Aβ4213myc, produced from fDHFR-UbR48-X-Aβ4213myc
(X=Asp, Val, Arg-Asp, Met), in wt, ate1Δ, and ubr1Δ strains of S. cerevisiae. Upper panels:
immunoblotting with anti-myc antibody. Lower panels: immunoblotting with anti-flag
antibody.
See also Figure S4.
Brower et al. Page 21
Mol Cell. Author manuscript; available in PMC 2014 April 25.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 5. Untagged, N-terminally Arginylated Human Aβ42 in Mouse Brains
(A) Antibody (antiR-Aβ) specific for RDAEFRHDSGYC was examined by dot assay with
Nt-arginylated Aβ and BRCA1 peptides (see the main text).
(B) Immunoblotting of extracts from the indicated ate1Δ or ubr1Δ yeast strains expressing
X-Aβ4213myc, produced in vivo from fDHFR-UbR48-X-Aβ4213myc (X=Asp, Arg-Asp).
Upper panel: immunoblotting with antiR-Aβ antibody, characterized in A. Lower panel:
immunoblotting with anti-myc antibody.
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(C) X-Aβ4213myc was produced from fDHFR-UbR48-X-Aβ4213myc (X=Arg-Asp, Met, Asp)
in the wt, Ate1−/−, or Ubr1−/− Ubr2−/− mouse EF cell lines, followed by SDS-PAGE of cell
extracts and immunoblotting with anti-myc antibody.
(D) Immunoblotting with anti-4G8 (recognizing total Aβ) of the indicated brain extracts
from either 5xFAD or non-Tg (nontransgenic) mice. Also shown are immunoblots with
antibody to GAPDH (loading controls).
(E) Untagged, Nt-arginylated human Aβ42 in 70% formic acid (FA) extracts from mouse
and human brains, detected by immunoblotting with antiR-Aβ. Lanes 1 and 2, FA extracts
from brains of non-Tg and 5xFAD mice, respectively, that were treated with inhibitors of
proteasome and neprilysin 12 hrs before harvesting brains. Lane 3 and 4, FA extracts from
the cortices of a human AD patient and a non-AD control, respectively. Lane 5, same as lane
2 but from 5xFAD mice that had not been treated with protease inhibitors. Lane 6, in vitro
Nt-arginylated Arg-Asp Aβ42 (see Figure 4D), a positive control.
See also Figure S4.
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